{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:15:37Z","timestamp":1783473337707,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.xphs.2018.01.023","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T07:31:15Z","timestamp":1517902275000},"page":"1572-1576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Safety and Tolerability of Topically Delivered Kynurenic Acid in Humans. A Phase 1 Randomized Double-Blind Clinical Trial"],"prefix":"10.1016","volume":"107","author":[{"given":"Anthony","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hartwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Ghahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10052","key":"10.1016\/j.xphs.2018.01.023_bib1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(16)31406-4","article-title":"Hypertrophic scarring: the greatest unmet challenge after burn injury","volume":"388","author":"Finnerty","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.xphs.2018.01.023_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/jid.2013.303","article-title":"Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in\u00a0vivo","volume":"134","author":"Li","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.xphs.2018.01.023_bib3","doi-asserted-by":"crossref","first-page":"e91955","DOI":"10.1371\/journal.pone.0091955","article-title":"Anti-scarring properties of different tryptophan derivatives","volume":"9","author":"Poormasjedi-Meibod","year":"2014","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.xphs.2018.01.023_bib4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2174\/1568026611209061797","article-title":"Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction","volume":"12","author":"Szalardy","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"10.1016\/j.xphs.2018.01.023_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/jir.2007.0104","article-title":"Improved scar in postburn patients following interferon-alpha2b treatment is associated with decreased angiogenesis mediated by vascular endothelial growth factor","volume":"28","author":"Wang","year":"2008","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.xphs.2018.01.023_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/BCR.0000000000000548","article-title":"Scar management following burn injury","volume":"38","author":"Tredget","year":"2017","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.xphs.2018.01.023_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4137\/IJTR.S12536","article-title":"Kynurenic acid in the digestive system \u2013 new facts, New challenges","volume":"6","author":"Turski","year":"2013","journal-title":"Int J Tryptophan Res"},{"issue":"12","key":"10.1016\/j.xphs.2018.01.023_bib8","first-page":"968","article-title":"Kynurenic acid concentration in blood and urine during normal pregnancy","volume":"69","author":"Milart","year":"1998","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.xphs.2018.01.023_bib9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1096\/fj.02-0103fje","article-title":"Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring","volume":"16","author":"Huang","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.xphs.2018.01.023_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/BCR.0b013e31819a6369","article-title":"A\u00a0novel TGF-beta antagonist speeds reepithelialization and reduces scarring of partial thickness porcine burns","volume":"30","author":"Singer","year":"2009","journal-title":"J\u00a0Burn Care Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918300662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918300662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T14:28:53Z","timestamp":1559917733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918300662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0022354918300662"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.01.023","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Safety and Tolerability of Topically Delivered Kynurenic Acid in Humans. A Phase 1 Randomized Double-Blind Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}